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ABSTRACT:  A variety of rist factors have been suspected for causing the coronary heart 
disease.  406 cases of both sex groups with age range of 35 to 55 years were selected from three 
distinct localities of varanasi city.  Individuals who reported single or more risk factors f CHD 
were isolated from the population of the particular areas. After a detailed preliminary screening 
of the subjects various physical, physiological, psychological and biochemical measurements 
were carried out.  O the basis of initial findings, the cases who sowed abnormal lipid profile with 
dominant psychological involvement were given the organic extract of Inula racemosa 
(Pushkarmool), commiphora mukul (Guggulu), centella asiatica (Mandukaparni) and 
Hypericum perforatum (Basant in prescribed doses continuously for 6 moths. Correction in the 
lipid profile including triglycerides, blood pressure and the psychological factors like anxiety 
and depression to a significant level following least drugs treatment indicated the 
cardioprotective and therapeutic effects of the present formulation. 
 
Hence, by modifying the coronary risk factors, the incidence of CD can be minimized to a great 
extent as well as the test formulation may also be advocated in the prevention and management 
of CHD. 
 
INTRODUCTION 
 
The risk factor concept implies tat a person 
with at least one risk factor for coronary 
heart disease is more may appear so earlier 
in comparison to a person with on  any risk 
factor.  The presence of multiple risk factors 
further accelerates the high occurrence of 
atherosclerosis associated with multiple 
pathology.  Hypercholesterolemia, 
hyperglycemia (diabetes), high calory intake 
wit least physical exercise, hypertension and 
cigratte smoking etc., are the most potent 
causative fat ors of CHD. The age, Sex and 
genetic factors are considered as the 
irreversible risk factors for CHD. Genetic 
factors have been observed to direct effects 
on arterial wall cell structure and 
metabolism or indirectly act to manifest 
hypertension, hyperlipidemia, diabetes and 
obesity (YLA Herttuala, 1991). 
 
Hypercholesterolemia and 
hypertriglyceridemia are the most important 
abnormalities causing the event of 
atherosclerosis.  A strong correlation 
between the cholesterol concentration and 
incidence of ischaemic heart diseases has 
been established which suggest that the 
increasing risk of CHD can be detected 
when the cholesterol level is higher than 200 
mg/dl for the age group of 40 to 49 years 
(Bierman, 1993). 
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According to castelli et al (1986), 
Cholesterol levels in men below age of 40 
years are closely related to the future 
occurance of CHD.  The multiple risk factor 
intervention trial has reported that the men 
with cholesterol levels of 240 mg/dl have a 
higher increase in risk of CHD death in 
comparison to men with a cholesterol level 
below 200 mg/dl. 
 
As regards prevention and management of 
coronary risk factors are concerned. 
Following three basic steps appear to be 
taken into consideration:- 
 
1. Prevention of occurance of adverse risk 
factors of CHD, 2. management of 
established adverse risk factors before the 
clinical manifestation of CHD 3. 
Management of coronary risk factors after 
the clinical manifestation. 
 
Keeping the above facts in view an earl 
detection of coronary risk factors was 
carried out and the individuals found at risk 
were administered herbal formulation for its 
prevention and management to reduce the 
incidence of any severity of coronary heart 
disease. 
 
MATERIAL AND METHOD: 
 
406 individuals of both sexes found at risk 
of CHD were selected from there distinct 
locality of varanasi cit in order to evaluate 
the clinical efficacy of an indigenous 
compound formaulation containing 
pushkarmool Guggulu, Mandukparni and 
Basant. Out of the selected 406 cases, 297 
were males and remaining 109 were 
females. To assess the beneficial role of the 
test formulation, 57 males and 28 females 
showing single or multiple coronary risk 
factor were kept on placebo treatment. 
 
Following a detailed preliminary screening, 
the comprehensive clinical examinations of 
all the individuals under stud were assessed 
on certain biochemical and psychological 
parameters.  Total lipid profile including 
triglycerides, anxiety and depression scores 
were recorded before introducing the drug 
treatment.  Different factions of lipo-
proteins were measured following the 
method developed by Reinhold (1965).   
Anxiety and depression scores were 
determined as per the standard scales. 
 
The present test formulation containing the 
organic extract of medicinally important part 
of certain plants in the following doses was 
selected to be used in suitable capsule form 
of 500mg. 
 
1.  Root extract of pushkarmool (Inula 
racemosa) = 3.0 mg/kg 
2.  Gum-Resin (Niryas) extract of 
Guggulu (Commiphora mukul) = 
7.0mg/kg. 
3.  Whole plant extract of mandukaparni 
(Centella asiatica) = 8.0mg/kg 
4.  Leaf extract of basant (Hypericum 
perforatum) = 0mg/kg. 
 
Total = 20.00 mg/kg 
 
The above capsules were prepared by filling 
the mixture of the extracted part of the plant 
drugs as indicated and were orally 
administered in the divided doses 
continuously for six month. Placebo 
capsules were also prepared similar to the 
test drug by using the dextrin powder and 
were introduced to the placebo group. 
 
Successive follow-up studies upto six 
months were carried out with the recordings 
of different parameters at the interval of 
each month.  At the end of six months, the 
results were statistically analysed and 
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compared wit each other following students 
paired t-test. 
 
RESULTS AND OBSERVATIONS: 
 
The test compound drug brought about 
significant improvement in specific clinical 
features like nervouseness, insomnia, 
palpitation tremors, irritability and earl 
fatigue. However placebo series did not 
exert any significant change and rather 
certain conditions were found more 
deteriorated in majority of the cases (Table -
1 systolic and diastolic blood pressure shoed 
a considerable declining trend in the treated 
group at the end of therapy while in placebo 
group no  such change could be noticed 
(Table -2) 
 
At the basal level, total cholesterol was 
found towards higher side wile the HDL –c 
showed comparatively low level indicating 
higher risk of CHD than the normal 
individuals.  After six months of drug 
treatment the TC and HDL-c ratio was 
corrected significantly (Table -3) 
 
When the different fractions of lipoprotein 
cholesterol were measured a high value of 
LDL-c and VLDL-c was recorded. 
Triglycerides also exhibited higher level 
indicating the risk of CHD of the 
individuals.  The test drug sowed beneficial 
effect in reducing the above levels (Table -
4). 
 
A high anxiety and depression score was 
noticed in majority of the cases. Following 
six months of test drug treatment that 
individuals showed a significant 
improvement in the psychic involvement 
indicating the relaxed state of mind and 
reduced anxiety and stress caused due to 
varying reasons (Table -5) 
 
The continuous use of the present herbal 
formulation did not sow any adverse effect. 
 
DISCUSSION: 
 
The prevention and treatment of risk factors 
are the fundamental approach in the 
management of coronary heart diseases.   
Hypercholesterolemia and 
hypertriglycerdemia are the two important 
factors that have been very clearly indicated 
to be responsible for the development of 
atherosclerotic lesion of coronary artery 
leading to myocardial infraction.  Apart 
from the hyperlipidemia and 
hypertriglycerdemia that are also associated 
with obesity and hypertension, 
hypertriglycerdemia also plays significant 
role in the precipitation of coronary heart 
disease (Glomset et al. 1980). The presence 
of other risk factors has been reported by 
several workers to progress the 
atherosclerotic changes of coronary vessels 
and precipitates the severity of myocardial 
ischaemia in CD patients (Castelli et al 
1986). 
 
Various studies have suggested that essential 
hypertension is one of the major risk factor 
for the incidence of coronary heart disease. 
Heredity, age, anxiety, stress and strain, 
smoking, obesity, alcohol intake etc.  are 
most often found to be the factors 
responsible for the onset of essential 
hypertension (Healton et al 1984, Grundy et 
al 1979). Thus it seems to be essential that 
earl onset of hypertension should be 
manages effectively. 
 
It is observed that stress of modern society 
leads to serious health hazards and 
ultimately precipitates the incidence of 
coronary heart disease. Anxiety and 
depression directly reflecting the emotional 
conflicts in day today life further pogress the 
severity of disease prognosis. 
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Hence, the individuals at relatively high risk 
of developing coronary heart disease (CHD) 
require a careful medical interventions for 
its management/modification.  Several 
evidences indicate that reducing the 
cigarette smoking helps fairly a rapid 
decline in the incidence of heart attack to the 
persons who never smoked (Day research 
group 1990, Dayton et al 1969, Collins et al 
1992).  There is strong evidence that 
effective treatment of moderate and high 
degrees of hypertension result in lower 
mortality particularly form strokes and 
congestive heart failure (Muldoon et al 
1990).  A major multicentric trial has shown 
tat reduction of hypercholesterolemia 
reduces that reduction of 
hypercholesterolemia reduces that risk of 
CHD. Similarly, reduction of obesity also 
minimizes the mortality rate CHD. 
 
Thus, unless the risk factors associated with 
CHD are manages, it is not possible to 
prevent the incidence of coronary heart 
disease. Many drug and non drug methods 
have been advocated for the prevention and 
management of CHD. Dietary regulation, 
adequate, management of diabetes mellitus, 
reduction in body weight, reducing alcohol 
and tobacco intake etc.  can definitely 
minimize the rate of CHD occurance. 
 
Many drug therapy used as anti-
hypertensive vasodilatory, anti-arrhythmic 
agents are although  being practiced greatly, 
but the application of such synthetic 
chemical agents are limited as their 
prolonged use are claimed to produce 
untoward effects in biological system.  In 
the recent past, various available drugs used 
for the management of hypercholesterolemia 
and hypertriglyceridemia have been abused 
due to tremendous adverse effect they 
produce on their long term administration.   
Hence there is an urgent need of some safer 
remedial measures for the management of 
lipid disorders which are the most common 
causative factors of CHD. 
 
In the present series of stud, the herbal test 
formulation has shown beneficial effect 
among the selected individuals at risk of 
CHD by modifying the blood pressure 
levels, different fractions of cholesterol and 
by correcting the deteriorated psychic status. 
Increase in the levels of HDL –c and 
decrease in TC following test drug treatment 
without an adverse effect indicates the 
applicability in the proper and safe 
management of abnormal lipid metabolism 
among the individuals at risk of CHD. 
 
The most important and noticeable finding 
of this stud is the correction of TC, DL –c 
ratio anxiety and depression scores in the 
patients following test drug treatment.  Thus, 
the test formulation besides having 
beneficial role in the regulation of abnormal 
lipid metabolism, which is the most 
important risk factor in the occurance of 
CHD. Directly or indirectly it has capacity 
to reduce the anxiety and stress with the 
result it causes reduction in blood pressure, 
anxiety level and depression score. Such 
effects indicate that the test formulation viz. 
I racemosa (Pushkarmool) as anti-anginal, 
cardiotonic, hypolipidaemic and 
hypoglyceamic, and C. mukul (Guggulu) as 
potent anti-atherotic, hypolipidaemic, 
hepatotonic, diuretic and general 
strengthening agents useful in prevention 
and treatment of ischaemic heart disease 
(Satyavati et al 1976, 1997 Sharma 1994.) 
Similarly, reports are also available for c. 
asiatica (Mandukaparni) an anxiolytic, brain 
tonic, general vitaliser and cardiotonic 
(Sharma 1994), and H. Perforatum (Basant) 
as mood elevation anti-depressant (Agrawal 
et al 1994), anti- oxidant (Tripathi et al 
1999) diuretic, hypotensive and cardiotonic 
agents (Sharma 1994, Satyavati et al 1997). 
pages 48 - 57  5
With the combination of above properties, 
the test formulation, containing the above 
ingredients and showing beneficial effect in 
the psychosomatic of CHD patients without 
an adverse effect in the administered 
dosages, may be a drug f choice for 
minimising the risk of coronary heart 
disease. 
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Table -1 Changes in various clinical symptomatology under influence of test formulation among the individuals at coronary risk. 
 
 
Clinical symptomatology 
Nervousness Insomnia Palpitation Tremors Irritability Early obesity  Fatiguability
Group No. 
of 
cases 
 
B  A  B A B A B A B A B A B A B  A 
M 57  71%  80% 79% 76%  57%  49% 62% 60%  77% 79% 66% 65% 39% 39%    Placebo 
Treated  F 28  93%  94% 52% 48%  64%  67% 68% 67%  61% 64% 50% 48% 48% 48%  49% 
M 297  70%  25% 82% 48%  68%  30% 67% 24%  79% 34% 72% 28% 36% 25%    Test 
drug 
Treated 
F 109  78% 
37% 
 
 
89% 42% 77% 36% 80% 35% 84% 29% 81% 34% 47% 33%   
A= After therapy,   B= Before Therapy M= Male, F= Female 
 
 
 
Table 2:  Effect of Test formulation on blood pressure levels among the individuals at coronary risk 
 
Systolic B.P. (mm Hg)  Diastolic B.P. (mm Hg)  Groups No. 
of 
cases 
 
 
 
Before therapy 
Therapy 
After six 
months 
therapy 
Camp Before 
Vs Six month 
therapy 
Before 
therapy 
Therapy 
After six months 
therapy 
Camp 
Before Vs 
Six month 
therapy 
M  57  158.48 ± 12.02  162.75 ± 13.39  P>0.05  94.36 ± 6.04  95.39 ± 6.85  P<0.05  Placebo 
Treated  F  28  152.65 ± 14.38  158.80 ± 13.78  P>0.05  92.88 ± 4.75  93.2 ± 5.14  P<0.05 
M  297  160.44 ± 12.90  134.35 ± 920  P>0.001  94.38 ± 5.34  86.40 ± 5.82  P<0.001  Test 
drug 
Treated 
F  109  157.95 ± 10.36  13604 ± 7.85  P>0.001  92.75 ± 5.16  85.34 ± 4.72  P<0.001 
 
   M= Male, F= Female 
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Table 3:  Effect of Test formulation on TC and HDL-c among the individuals at coronary risk 
 
Before treatment  After 6 months treatment  Groups No. 
of 
cases 
 
 
 
TC (mg/dl)  HDL-c(mg/dl)  TC & HDL-c risk 
factor 
TC (mg/dl)  HDL-c(mg/dl)  TC & HDL-c 
risk factor 
M  57  240.70 ± 22.35  62.68 ± 6.78  3.84  254.65 ± 20.05  66.14 ± 6.12  3.85  Placebo 
Treated 
F  28  244.60 ± 21.45  63.20 ± 5.25  3.87  258.05 ± 21.35  66.34 ± 5.14  3.89 
M  297  248.25 ± 21.43  63.98 ± 4.98  3.88  198.84 ± 18.96  67.18 ± 5.14  2.96  Test 
drug 
Treated  F  109  253.65 ± 19.37  65.04 ± .37  3.90  19..35 ± 19.38  68.23 ± 6.12  2.79 
 
    M= Male, F= Female 
 
Table 4:  Effect of Test formulation on LDL-c, VLDL-c  and triglycerides among the individuals at coronary risk 
 
LDL-c (mg/dl)  VLDL-c (mg/dl) Triglycerides  (mg/dl)  Groups No. 
of 
cases 
 
 
 
Before 
treatment 
After 6 months 
treatment 
Before 
treatment 
After 6 months 
treatment 
Before 
treatment 
After 6 months 
treatment 
M  57  128.72 ± 20.75  137.87 ± 23.71  56.32 ± 8.30  60.72 ± 6.12  180.14 ± 25.31  181.95 ± 27.30  Placebo 
Treated 
F  28  126.35 ± 16.44  130.20 ± 15.84  54.65 ± 7.32  60.92± 5.02  175.30 ± 2.72  177.32 ± 28.31 
M  297  130.67 ± 14.02  103.79 ± 13.92  60.72 ± 7.94  40.38 ± 5.41  182.94 ± 23.85  161.72 ± 22.945  Test 
drug 
Treated  F  109  128.42 ± 15.11   95.87 ± 10.88  64.85 ± 6.48  36.75 ± 4.86  180.36 ± 22.92  158.22 ± 21.42 
Comparison  
(Before Vs 6 months treatment) 
P>0.05 
P>0.05 
P<0.001 
P<0.001 
 
 
P>0.05 
P>0.05 
P<0.001 
P<0.001 
 
 
P>0.05 
P>0.05 
P<0.001 
P<0.001 
 
    M= Male, F= Female 
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Table 5:  Effect of Test formulation on anxiety and depression score among the individuals at coronary risk 
 
Anxiety Level (Score)  Depression score  Groups No. 
of 
cases 
 
 
 
Before treatment  After 6 months 
treatment 
Comp before Vs 6 
months treatment 
Before 
treatment 
After 6 months 
treatment 
Comp before 
Vs 6 months 
treatment 
M  57  65.38 ± 6.39  4.80 ± 7.78  P>0.05  33.88 ± 4.38  34.77± 4.92  P>0.05  Placebo 
Treated 
F  28  63.92 ± 5.99   64.72 ± 712  P>0.05  35.34 ± 3.22  36.70 ± 5.04  P>0.05 
M  297  64.94 ± 5.88  52.44 ± 4.20  P<0.001  34.05 ± 3.12  27.92 ± 3.04  P<0.001  Test 
drug 
Treated  F  109  61.74 ± 6.07  51.85 ± 4.22  P<0.001  35.38 ± 4.10  26.95 ± 3.11  P<0.001 
 
    M= Male, F= Female   
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